PRESS RELEASE: co.don® AG - Application filed for EU-wide approval for the articular cartilage product chondrosphere®

co.don AG / co.don® AG - Application filed for EU-wide approval for the articular cartilage product chondrosphere® . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Teltow, 08. January 2013

co.don® AG has submitted its application for EU marketing authorisation for the articular cartilage product chondrosphere® to the relevant committee of the European Medicines Agency in London.

The official approval procedure began on 26.12.2012.

A European regulation stipulates that tissue products derived from biotechnology processes, which include the tissue transplants from co.don AG, require central marketing authorisation from the European Commission.

Now that co.don® AG has filed the extensive approval documentation by the end of 2012, in line with its own internal timetable, the European Medicines Agency is responsible for carrying out the scientific evaluation of the application and making a recommendation on marketing authorisation to the European Commission.

The product can still be sold in Germany, the main sales market for co.don® AG, as the company applied for the appropriate approval from the national German federal authority before the deadline. At the same time co.don® AG is intensifying its marketing and sales activities in non-EU member states both inside and outside Europe.

About co.don® AG:

The company is based in Teltow, Brandenburg, and was founded in 1993. Since 2001 the biopharmaceutical specialist has been listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). co.don AG(®) uses tissue engineering - the cultivation and growth of autologous tissue cells - to develop innovative products and therapeutic concepts for the orthopaedic and neurosurgical markets. The cell-based biological drugs (autologous cell transplants for articular cartilage and intervertebral disks) are produced without the use of antibiotics, growth factors and genetic engineering. The Executive Board of co.don(®) AG is made up of Dr Andreas Baltrusch (CEO) and Vilma Methner (COO, CSO).

Further information is also available from: www.codon.de

Press contact BrunoMedia GmbH R.-D. Brunowsky

Telephone: 01704621440

Email: brunowsky@brunomedia.de

Press release (PDF): http://hugin.info/132731/R/1668926/542136.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: co.don AG via Thomson Reuters ONE [HUG#1668926]

--- End of Message ---

co.don AG Warthestr. 21 Teltow Germany

WKN: A1K022;ISIN: DE000A1K0227; Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Niedersächsische Börse zu Hannover, General Standard in Frankfurter Wertpapierbörse, Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.codon.de (END) Dow Jones Newswires

   January 08, 2013 05:54 ET (10:54 GMT)- - 05 54 AM EST 01-08-13